Professor Philip Barter MD, PhD

Philip Barter is the Director of The Heart Research Institute, in Sydney, Australia and is also a Professor of Medicine at the University of Sydney. He graduated in medicine from the University of Adelaide and gained his PhD from the Australian National University. He is a fellow of the Royal Australasian College of Physicians. He has previously held positions in research institutes and universities in Australia and the USA. He is a member of the Board of Directors of the International Task Force for Prevention of Coronary Heart Disease and Secretary of the International Atherosclerosis Society.

His basic research interests are plasma lipids and lipoproteins, specifically high density lipoproteins, the factors that regulate them and the mechanism by which they protect against cardiovascular disease. His clinical research involves participation in clinical trials of lipid-lowering agents. He is a member of the steering committee of the TNT Study and is chairman of the steering committee of the recently concluded ILLUMINATE trial. He has published more than 200 research papers on plasma lipids and lipoproteins, their metabolism, regulation, function and relationship to atherosclerosis.


Most recent publications:

Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, Lopez-Sendon J, Mosca L, Tardif J-C, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357, 2109-22. www.ncbi.nlm.nih.gov/sites/entrez

Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJP, Bittner V, Fruchart J-C, for the treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol and cardiovascular events. N Engl J Med 2007; 357:1301-10.
www.ncbi.nlm.nih.gov/sites/entrez

Barter P, Rye KA. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol 2007 Aug 23; [Epub ahead of print]
www.ncbi.nlm.nih.gov/sites/entrez

Settasatian N, Barter PJ, Rye KA. Remodelling of apolipoprotein E-containing spherical reconstituted high density lipoproteins by phospholipid transfer protein. J Lipid Res 2007 Oct 5;
www.ncbi.nlm.nih.gov/sites/entrez


Most cited publications:

Barter PJ, Brewer HB Jr , Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23:160-7
www.ncbi.nlm.nih.gov/sites/entrez

Barter PJ, Kastelein JP. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J Amer Coll Cardiol 2006; 47 492-9.
www.ncbi.nlm.nih.gov/sites/entrez

Barter P, Kastelein J, Nunn A, Hobbs R and Future Forum Editorial Board. High density lipoproteins (HDLs) and atherosclerosis: the unanswered questions. Atherosclerosis 2003;168:195-211.
www.ncbi.nlm.nih.gov/sites/entrez

Rye KA, Wee K, Curtiss LK, Bonnet DJ, Barter PJ. Apolipoprotein A-II inhibits high density lipoprotein remodeling and lipid-poor apolipoprotein A-I formation. J Biol Chem 2003;278:22530-6.
www.ncbi.nlm.nih.gov/sites/entrez

Rye KA, Barter PJ. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol 2004;24:421-8.
www.ncbi.nlm.nih.gov/sites/entrez